Review
Oncology
Andrey Rubanov, Pietro Berico, Eva Hernando
Summary: Melanoma is an aggressive skin cancer that relies on early detection for successful treatment. Genetic drivers of melanoma have been identified and targeted therapies have significantly improved patient outcomes. However, resistance to therapy, caused by both genetic alterations and epigenetic reprogramming, remains a challenge.
Review
Biochemistry & Molecular Biology
Merve Kulbay, Adeline Paimboeuf, Derman Ozdemir, Jacques Bernier
Summary: The article summarizes the mutations in apoptotic pathways associated with cancer development, as well as the targeted therapies currently available or in trial.
JOURNAL OF CELLULAR BIOCHEMISTRY
(2022)
Editorial Material
Biochemistry & Molecular Biology
Chih-Hsin Tang
Summary: Osteoporosis is a common skeletal disorder caused by an imbalance between bone resorption and bone formation. Current treatments include bone resorption inhibitors and anabolic agents, which can have significant side effects, highlighting the importance of further research into the pathogenesis of the disease and the development of novel therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Louise Marchandet, Morgane Lallier, Celine Charrier, Marc Baud'huin, Benjamin Ory, Francois Lamoureux
Summary: Osteosarcoma is the most common primary bone tumor affecting children and adolescents, with resistance being one of the reasons for treatment failure. Understanding the molecular mechanisms of resistance is key to developing new strategies to improve patient outcomes.
Review
Oncology
Jing Wang, Zhijie Luo, Lizhu Lin, Xinbing Sui, Lili Yu, Cong Xu, Ruonan Zhang, Ziming Zhao, Qianru Zhu, Bo An, Qiao Wang, Bi Chen, Elaine Lai-Han Leung, Qibiao Wu
Summary: Anoikis, the programmed cell death process caused by the loss of interaction between cells and the extracellular matrix, is crucial to prevent tumor metastasis. In lung cancer, various factors such as extracellular matrix composition, cell adhesion-related proteins, cytoskeletal regulators, and epithelial-mesenchymal transition, contribute to the regulation of anoikis. Understanding the molecular mechanisms and regulators involved in anoikis can provide insights for the development of targeted therapies for lung cancer metastasis.
Review
Pharmacology & Pharmacy
Kexin Wang, Qingyuan Liu, Mingyu Tang, Guangdong Qi, Chong Qiu, Yan Huang, Weiran Yu, Wei Wang, Hualin Sun, Xuejun Ni, Yuntian Shen, Xingxing Fang
Summary: Chronic kidney disease (CKD) is a high-risk chronic catabolic disease with high morbidity and mortality. CKD is accompanied by many complications, leading to a poor quality of life and even threatening the life of patients. Muscle atrophy is a common complication of CKD.
BIOCHEMICAL PHARMACOLOGY
(2023)
Review
Oncology
Xiaoyun He, Gaoyan Kuang, Yongrong Wu, Chunlin Ou
Summary: Exosomes are small vesicles secreted by cells and can carry various cargo including RNA, DNA, proteins, and metabolites. Studies have shown that exosomal microRNAs play a crucial role in the progression of diseases such as diabetes mellitus, affecting processes like pancreatic beta-cell injury and insulin resistance. Understanding the mechanisms of exosomal miRNAs in diabetes mellitus can provide valuable insights for identifying diagnostic biomarkers and drug targets.
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Article
Dermatology
Ozgecan Dulgar, Tugce Kutuk, Zeynep Eroglu
Summary: Several strategies have been explored to overcome resistance mechanisms to BRAF/MEK inhibition in melanoma, including changing dosing regimens, adding other kinase inhibitors, and using anti-PD-1 immunotherapy in combination therapy.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2021)
Review
Oncology
Zihe Dong, Zhipeng Liao, Yonglin He, Chengye Wu, Zixiang Meng, Baolong Qin, Ge Xu, Zeyang Li, Tianxin Sun, Yuyan Wen, Guangjie Li
Summary: This paper reviews the role of microRNAs in the pathogenesis of osteosarcoma and their clinical value, aiming to provide a new research direction for diagnosing and treating osteosarcoma and achieving a better prognosis.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2022)
Article
Oncology
Sara Peixoto da Silva, Hugo R. Caires, Rui Bergantim, Jose E. Guimaraes, M. Helena Vasconcelos
Summary: This review discusses the role of miRNAs in hematological malignancies, including their important role in drug resistance and their potential clinical applications.
SEMINARS IN CANCER BIOLOGY
(2022)
Review
Pharmacology & Pharmacy
Xia Zhou, Xiaokang Wang, Nan Li, Yu Guo, Xiaolin Yang, Yuhe Lei
Summary: Neuroblastoma is a common pediatric solid tumor that threatens children's health and is responsible for about 15% of childhood cancer-related deaths in the US. Despite the development of multiple therapies, resistance to treatment remains a challenge, leading to treatment failure and cancer relapse. Understanding the mechanisms of therapy resistance and discovering reversal strategies are urgent tasks in improving the prognosis for neuroblastoma patients.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Milena Rizzo
Summary: One of the main challenges in the treatment of metastatic prostate cancer is the development of resistance to docetaxel, the gold standard therapy. Non-coding RNA appears to play a significant role in the processes leading to docetaxel resistance.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2021)
Article
Cell Biology
Christine Parseghian, Madhulika Eluri, Scott Kopetz, Kanwal Raghav
Summary: This article discusses the development of acquired resistance to anti-EGFR therapies, highlighting the predominance of transcriptomic mechanisms of resistance in first-line treatment and acquired MAPK mutations in later-line treatment. It emphasizes the importance of prospective studies guided by acquired MAPK mutations in evaluating anti-EGFR rechallenge strategies.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Review
Psychology, Multidisciplinary
Martina de Witte, Hod Orkibi, Rebecca Zarate, Vicky Karkou, Nisha Sajnani, Bani Malhotra, Rainbow Tin Hung Ho, Girija Kaimal, Felicity A. Baker, Sabine C. Koch
Summary: Research on creative arts therapies, such as art therapy, music therapy, and dance/movement therapy, has shown positive impacts on psychological and physiological outcomes. However, there is still limited understanding of the specific therapeutic factors responsible for these effects. A scoping review of 67 studies was conducted to identify therapeutic factors unique to each CATs discipline, as well as common factors across all psychotherapy approaches, leading to the proposal of a framework consisting of 19 domains of CATs therapeutic factors.
FRONTIERS IN PSYCHOLOGY
(2021)
Review
Oncology
Sabrina Rizzolio, Silvia Giordano, Simona Corso
Summary: In the last two decades, targeted drugs have revolutionized clinical oncology. However, primary and acquired resistance to these therapies has become a significant limitation, with cancer-associated fibroblasts (CAFs) playing a crucial role. CAFs not only contribute to tumor stroma structure, but also release various molecules that impact tumor properties, including response to drug treatment. The role of CAFs in resistance to targeted therapies, particularly molecular therapies, has been overlooked.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Michela Camilla Milanesio, Silvia Giordano, Giorgio Valabrega
Review
Surgery
Rossella Reddavid, Simona Corso, Daniel Moya-Rull, Silvia Giordano, Maurizio Degiuli
UPDATES IN SURGERY
(2020)
Article
Oncology
Sabrina Rizzolio, Simona Corso, Silvia Giordano, Luca Tamagnone
Article
Oncology
Claudia Orru, Andrea Perra, Marta Anna Kowalik, Sabrina Rizzolio, Elisabetta Puliga, Lavinia Cabras, Silvia Giordano, Amedeo Columbano
Review
Oncology
Claudia Orru, Silvia Giordano, Amedeo Columbano
Article
Genetics & Heredity
Xing Yi Woo, Jessica Giordano, Anuj Srivastava, Zi-Ming Zhao, Michael W. Lloyd, Roebi de Bruijn, Yun-Suhk Suh, Rajesh Patidar, Li Chen, Sandra Scherer, Matthew H. Bailey, Chieh-Hsiang Yang, Emilio Cortes-Sanchez, Yuanxin Xi, Jing Wang, Jayamanna Wickramasinghe, Andrew V. Kossenkov, Vito W. Rebecca, Hua Sun, R. Jay Mashl, Sherri R. Davies, Ryan Jeon, Christian Frech, Jelena Randjelovic, Jacqueline Rosains, Francesco Galimi, Andrea Bertotti, Adam Lafferty, Alice C. O'Farrell, Elodie Modave, Diether Lambrechts, Petra ter Brugge, Violeta Serra, Elisabetta Marangoni, Rania El Botty, Hyunsoo Kim, Jong-Il Kim, Han-Kwang Yang, Charles Lee, Dennis A. Dean, Brandi Davis-Dusenbery, Yvonne A. Evrard, James H. Doroshow, Alana L. Welm, Bryan E. Welm, Michael T. Lewis, Bingliang Fang, Jack A. Roth, Funda Meric-Bernstam, Meenhard Herlyn, Michael A. Davies, Li Ding, Shunqiang Li, Ramaswamy Govindan, Claudio Isella, Jeffrey A. Moscow, Livio Trusolino, Annette T. Byrne, Jos Jonkers, Carol J. Bult, Enzo Medico, Jeffrey H. Chuang
Summary: The analysis of copy number alterations in patient-derived xenografts (PDXs) and matched patient tumor samples reveals strong conservation of copy number alterations from patient tumors through late-passage PDXs, without systematic evolution driven by the mouse host. This suggests that PDX models are accurate in representing human cancer and that the mouse host does not significantly impact the copy number alterations during tumor evolution within the PDX model.
Article
Oncology
Nil Grunberg, Meirav Pevsner-Fischer, Tal Goshen-Lago, Judith Diment, Yaniv Stein, Hagar Lavon, Shimrit Mayer, Oshrat Levi-Galibov, Gil Friedman, Yifat Ofir-Birin, Li-Jyun Syu, Cristina Migliore, Eyal Shimoni, Salomon M. Stemmer, Baruch Brenner, Andrzej A. Dlugosz, David Lyden, Neta Regev-Rudzki, Irit Ben-Aharon, Ruth Scherz-Shouval
Summary: This study used RNA sequencing of CAFs from gastric cancer patients to identify a stromal gene signature associated with aggressive gastric cancer, with HSF1 playing a key regulatory role in this signature. HSF1 upregulates inhibin subunit beta A and thrombospondin 2, which are secreted in CAF-derived extracellular vesicles to promote cancer progression.
Article
Oncology
Simona Corso, Filippo Pietrantonio, Maria Apicella, Cristina Migliore, Daniela Conticelli, Annalisa Petrelli, Laura D'Errico, Stefania Durando, Daniel Moya-Rull, Sara E. Bellomo, Stefano Ughetto, Maurizio Degiuli, Rossella Reddavid, Uberto Fumagalli, Stefano De Pascale, Giovanni Sgroi, Emanuele Rausa, Gian Luca Baiocchi, Sarah Molfino, Giovanni De Manzoni, Maria Bencivenga, Salvatore Siena, Andrea Sartore-Bianchi, Federica Morano, Salvatore Corallo, Michele Prisciandaro, Maria Di Bartolomeo, Annunziata Gloghini, Silvia Marsoni, Antonino Sottile, Anna Sapino, Caterina Marchio, Asa Dahle-Smith, Zosia Miedzybrodzka, Jessica Lee, Siraj M. Ali, Jeffrey S. Ross, Brian M. Alexander, Vincent A. Miller, Russell Petty, Alexa B. Schrock, Silvia Giordano
Summary: The study highlights EGFR amplification as a driving factor of aggressive behavior and poor prognosis in gastric cancer, with EGFR inhibitors showing activity in patients with EGFR copy number gain. Additionally, the combination of EGFR and mTOR inhibitors shows promise in overcoming primary resistance mechanisms.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
Elisabetta Puliga, Simona Corso, Filippo Pietrantonio, Silvia Giordano
Summary: Gastric cancer is a significant contributor to the global burden of cancer, with microsatellite instable (MSI) tumors showing promising survival outcomes and potential for immune checkpoint inhibitors treatment. However, conflicting results have been reported in chemotherapy settings.
CANCER TREATMENT REVIEWS
(2021)
Article
Oncology
Stefano Ughetto, Cristina Migliore, Filippo Pietrantonio, Maria Apicella, Annalisa Petrelli, Laura D'Errico, Stefania Durando, Daniel Moya-Rull, Sara E. Bellomo, Sabrina Rizzolio, Tania Capeloa, Salvatore Ribisi, Maurizio Degiuli, Rossella Reddavid, Ida Rapa, Uberto Fumagalli, Stefano De Pascale, Dario Ribero, Carla Baronchelli, Giovanni Sgroi, Emanuele Rausa, Gian Luca Baiocchi, Sarah Molfino, Stefania Manenti, Maria Bencivenga, Michele Sacco, Claudia Castelli, Salvatore Siena, Andrea Sartore-Bianchi, Federica Tosi, Federica Morano, Alessandra Raimondi, Michele Prisciandaro, Annunziata Gloghini, Silvia Marsoni, Antonino Sottile, Ivana Sarotto, Anna Sapino, Caterina Marchio, Paola Cassoni, Simonetta Guarrera, Simona Corso, Silvia Giordano
Summary: This study demonstrates that in patients with HER2-amplified gastric cancer, a dual HER2 blockade is crucial for optimal efficacy, leading to complete and durable responses in most cases. A selected subpopulation of HER2-hyper-amplified GC patients could greatly benefit from this treatment strategy.
Review
Oncology
Rossella Reddavid, Simona Dagatti, Caterina Franco, Lucia Puca, Mariano Tomatis, Simona Corso, Silvia Giordano, Maurizio Degiuli
Summary: Despite the addition of molecular therapy in the clinical treatment of advanced and metastatic gastric cancer, the survival benefits of these novel therapies remain rather unclear, possibly due to inaccurate patient selection.
Article
Cell Biology
Rajesh Pal, Marta Anna Kowalik, Marina Serra, Cristina Migliore, Silvia Giordano, Amedeo Columbano, Andrea Perra
Summary: The study found that different regulatory mechanisms are at play for cell cycle progression in mouse hepatocytes following liver regeneration and primary hyperplasia, with miRNAs playing important roles in regulating liver cell proliferation.
CELL PROLIFERATION
(2022)
Article
Cell Biology
Enrico Berrino, Umberto Miglio, Sara Erika Bellomo, Carla Debernardi, Alberto Bragoni, Annalisa Petrelli, Eliano Cascardi, Silvia Giordano, Filippo Montemurro, Caterina Marchio, Tiziana Venesio, Anna Sapino
Summary: L1 reactivation is associated with aggressive features of breast cancer and worse clinical outcomes.
Article
Oncology
Filippo Pietrantonio, Paolo Manca, Sara Erika Bellomo, Simona Corso, Alessandra Raimondi, Enrico Berrino, Federica Morano, Cristina Migliore, Monica Niger, Lorenzo Castagnoli, Serenella Maria Pupa, Caterina Marchio, Maria Di Bartolomeo, Eleonora Restuccia, Chiara Lambertini, Josep Tabernero, Silvia Giordano
Summary: In the JACOB trial, the addition of pertuzumab to trastuzumab-chemotherapy did not significantly improve the survival of patients with metastatic HER2-positive gastric cancer. However, HER2 copy-number variation and AMNESIA panel may help in selecting patients who will benefit from HER2 inhibition. The analysis of HER2 CNV, HER2 expression, and AMNESIA showed correlations with overall response rate, progression-free survival, and overall survival.
CLINICAL CANCER RESEARCH
(2023)
